Get access

Potential New Indication for Ivabradine: Treatment of a Patient with Congenital Junctional Ectopic Tachycardia

Authors

  • SALEH AL-GHAMDI M.D.,

    1. Department of Pediatric Cardiology, Prince Sultan Cardiac Center
    Search for more papers by this author
  • MAJID I. AL-FAYYADH M.D.,

    1. Heart Center, King Faisal Specialist Hospital & Research Center and College of Medicine, King Saud University, Riyadh, Saudi Arabia
    Search for more papers by this author
  • ROBERT M. HAMILTON M.D., M.H.Sc.

    Corresponding author
    1. Department of Pediatrics, Labatt Family Heart Centre, The Hospital for Sick Children & Research Institute and University of Toronto, Toronto, Canada
    • Department of Pediatric Cardiology, Prince Sultan Cardiac Center
    Search for more papers by this author

  • No disclosures.

Address for correspondence: Robert M. Hamilton, M.D., Room 1725D, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1 X 8. Fax: 1-416-813-7547; E-mail: robert.hamilton@sickkids.ca

Potential New Indication for Ivabradine

Ivabradine is a new antiarrhythmic agent with direct inhibition of the pacemaker (If) current. It has been used extensively to decrease sinus rate in the treatment of cardiac failure, and also in a single case of atrial ectopic tachycardia in a child. Here we report the case of a 3-year-old girl with congenital junctional ectopic tachycardia (JET), resistant to conventional antiarrhythmic medications, who was successfully treated with ivabradine. We suggest that ivabradine can be an effective treatment for junctional automatic tachycardias and can be considered as a new line of therapy for this incessant form of tachycardia.

Ancillary